Loading...
Loading...
- FibroGen Inc FGEN released data from the MATTERHORN Phase 3 trial of roxadustat for anemia in patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS).
- The 140-patient study did not meet its primary endpoint.
- The study's primary endpoint was transfusion independence for ≥ 56 consecutive days during the first 28 weeks of treatment.
- The proportion of patients who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for the roxadustat arm compared to 33.3% for the placebo, but this difference was not statistically significant (p=0.217).
- The adverse event profile of roxadustat observed in the preliminary safety analysis was consistent with previous findings, and safety will be further evaluated at study completion.
- Roxadustat is an oral medication that promotes erythropoiesis, or red blood cell production.
- Earlier this week, FibroGen announced a non-dilutive term loan facility of up to $150 million from Morgan Stanley Tactical Value.
- The company expects to report topline data from the China Phase 3 study of roxadustat for chemotherapy-induced anemia (CIA) expected 2Q 2023.
- Price Action: FGEN shares are up 2.57% at $17.13 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
